Advances in systemic antifungal therapy.
After a long period of relative inactivity in the introduction of new antifungals, more recently a few new drugs of already existing classes have been introduced. These represent small or large advantages and differences compared with existing available alternative therapy for deep and systemic mycoses. The 3 newest drugs include posaconazole, micafungin, and anidulafungin, whose pharmacology, toxicology, and indications are presented.
Department of Medicine, Division of Infectious Diseases, Santa Clara Valley Medical Center, 751 South Bascom Avenue, San Jose, CA 95128-2699, USA. stevens@stanford.edu
David A
DA
Stevens
D000077612:Anidulafungin; D000935:Antifungal Agents / Q000009:adverse effects / Q000494:pharmacology*; D054714:Echinocandins / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D055666:Lipopeptides / Q000009:adverse effects / Q000494:pharmacology; D000077551:Micafungin; D009181:Mycoses / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D014230:Triazoles / Q000009:adverse effects / Q000494:pharmacology
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D014230:Triazoles; C101425:posaconazole; D000077612:Anidulafungin; D000077551:Micafungin